[HTML] spandidos-publications.com

[HTML][HTML] Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

Y Lei, W Guo, B Chen, L Chen… - Oncology …, 2018 - spandidos-publications.com
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced‑stage …
被引用次数：144 相关文章

Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer

Y Lei, W Guo, B Chen, L Chen, J Gong, W Li - Oncology Reports, 2018 - go.gale.com
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced-stage …

[引用][C] Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

Y Lei, W Guo, B Chen, L Chen, J Gong, W Li - Oncology Reports, 2018 - cir.nii.ac.jp
Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in
non‑small cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.

Y Lei, W Guo, B Chen, L Chen, J Gong, W Li - Oncology Reports, 2018 - europepmc.org
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced-stage …
[HTML] nih.gov

[HTML][HTML] Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer

Y Lei, W Guo, B Chen, L Chen, J Gong, W Li - Oncology Reports, 2018 - ncbi.nlm.nih.gov
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced-stage …

Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

Y Lei, W Guo, B Chen, L Chen, J Gong… - Oncology …, 2018 - pubmed.ncbi.nlm.nih.gov
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced‑stage …
[HTML] spandidos-publications.com

[HTML][HTML] Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

Y Lei, W Guo, B Chen, L Chen… - Oncology …, 2018 - spandidos-publications.com
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced‑stage …

Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer

Y Lei, W Guo, B Chen, L Chen, J Gong… - Oncology Reports, 2018 - search.proquest.com
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced-stage …
[PDF] semanticscholar.org

[PDF][PDF] Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

YI LEI, W GUO, B CHEN, LU CHEN, J GONG, W LI - pdfs.semanticscholar.org
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced-stage …